Hepatitis B Boosters Using A Different Product Vs. The Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference

Kentaro Iwata; Shunkichi Ikegaki; Yoji Hyodo; Hideaki Miyake;

RELATED

Related Papers     Patents    Grants    Venues    Experts    Cite    Share    Save

ABSTRACT

Hepatitis B vaccination is recommended for those receiving kidney transplants. When hepatitis B surface antibody (HBsAb) levels remain low, the booster dose of the vaccine should be considered. Some consider that the use of a different product as a booster might be beneficial to the patients, but the effectiveness of such a strategy has not been evaluated. The kidney transplant recipients (KTR) who received hepatitis B vaccines (Bimmugen or Heptavax-II), and failed to develop enough antibody titer and those who received additional vaccines, were enrolled in the study. Those who received a different product were compared with those who received the same product as the booster. The outcome is the seroconversion of hepatitis B surface antibody level ≧ 10 IU/mL. A total of 26 patients were non-responders after a receipt of three-dose hepatitis B vaccines. Among those, 15 received additional hepatitis B vaccine of the different product (crossover group), and 11 received the same product (non-crossover group). Only five patients (19.2%) had seroconversion after the booster doses, three in the crossover group (20%) and two in the non-crossover group (18.2%) (p = 1.0). In the Bayesian analysis, the medial posterior probability of the seroconversion rate of the crossover group was 23% (95% CrI: 7%-47%), whereas that of the non-crossover group was 14% (95% CrI: 2%-40%). The crossover strategy hepatitis B vaccines did not appear to lead to seroconversion of much significance among KTR. Other options to augment the protection should be investigated to protect these populations against the infection.

 Paraphrase     Questionfy     Wikify     Simplify     Summarize

Download